Reform-induced competition: Evaluating the impact on Swiss pharmacies and total drug costs

This paper explores the effect of increased competition on pharmacies induced by a regime change in two Swiss cities allowing physicians to self-dispense drugs. By merging detailed sales and survey data at the pharmacy level, a difference-in-differences estimation shows a significant and permanent loss of market share in prescribed drug revenue and profits. The decline is driven by drugs used for acute illnesses and is less pronounced for larger pharmacies. While generic drug sales decrease significantly, the more expensive brand-name drugs remain largely unaffected. I find evidence that pharmacies respond to increased competition by diversifying toward health services. Adding administrative physician data shows that the reform caused approximately CHF 19.5M in additional drug costs per year. My results demonstrate that more competition can result in higher drug costs for society.

Authors

Institutions

Publication Details

Journal
Journal of Health Economics
Published
2026-01-22
DOI
https://doi.org/10.1016/j.jhealeco.2026.103111
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reform-induced competition: Evaluating the impact on Swiss pharmacies and total drug costs

Marc Anderes
Journal of Health Economics
Pharmaceutical Economics and Policy
article

Reform-induced competition: Evaluating the impact on Swiss pharmacies and total drug costs

Marc Anderes
article en

Abstract

This paper explores the effect of increased competition on pharmacies induced by a regime change in two Swiss cities allowing physicians to self-dispense drugs. By merging detailed sales and survey data at the pharmacy level, a difference-in-differences estimation shows a significant and permanent loss of market share in prescribed drug revenue and profits. The decline is driven by drugs used for acute illnesses and is less pronounced for larger pharmacies. While generic drug sales decrease significantly, the more expensive brand-name drugs remain largely unaffected. I find evidence that pharmacies respond to increased competition by diversifying toward health services. Adding administrative physician data shows that the reform caused approximately CHF 19.5M in additional drug costs per year. My results demonstrate that more competition can result in higher drug costs for society.

Journal of Health EconomicsVol. 106
Swiss Finance Institute (CH)
Openalex Percentile: Top 84%
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.